A STUDY TO EVALUATE THE EFFICACY OF PROPRANOLOL IN BOOSTING IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA AND PANCREATIC ADENOCARCINOMA (BLOCKED)
- Registry ID
- IIT-0027
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- CROSS CANCER INSTITUTE - CANCER CARE ALBERTA
- Start date
- 2026-06-11
- Last update
- 2022-04-14
Conditions
- HEPATOCELLULAR CARCINOMA
- PANCREATIC ADENOCARCINOMA
- CHOLANGIOCARCINOMA
Related clinical trials
- A PHASE 1B/2, SAFETY LEAD-IN AND DOSE-EXPANSION, OPEN LABEL, MULTICENTER TRIAL INVESTIGATING THE SAFETY, TOLERABILITY, AND PRELIMINARY ACTIVITY OF IVOSIDENIB IN COMBINATION WITH DURVALUMAB AND GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY IN PARTICIPANTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION
- RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AND TREMELIMUMAB AND
SURGERY VERSUS RADIATION THERAPY FOLLOWED BY SURGERY FOR RESECTABLE
HEPATOCELLULAR CARCINOMA. A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL
(DARTS)
- PHASE 2 STUDY OF FUTIBATINIB 20 MG AND 16 MG IN PATIENTS WITH ADVANCED
CHOLANGIOCARCINOMA WITH FGFR2 FUSIONS OR REARRANGEMENTS
- A MULTICENTER, OPEN LABEL, NON-RANDOMIZED FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF BAY 3547926 ALONE, AND IN COMBINATION, IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
- PERIOPERATIVE THERAPY WITH DURVALUMAB PLUS TREMELIMUMAB FOR PATIENTS WITH RESECTABLE HEPATOCELLULAR CARCINOMA (HCC) - A PHASE II TRIAL (NEOTOMA)
- ATEZOLIZUMAB AND BEVACIZUMAB PRE-LIVER TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA BEYOND MILAN CRITERIA: A FEASIBILITY STUDY
View on source registry